MT-ND1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Hela cells, Primary antibody: P05070(MT-ND1 Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P05070(MT-ND1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P05070(MT-ND1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The MT-ND1 antibody targets the MT-ND1 protein (Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 1), a critical component of Complex I in the mitochondrial electron transport chain (ETC). Encoded by mitochondrial DNA (mtDNA), MT-ND1 plays a central role in oxidative phosphorylation, facilitating ATP production by transferring electrons from NADH to ubiquinone. Mutations in the MT-ND1 gene are linked to mitochondrial disorders, such as Leber’s hereditary optic neuropathy (LHON), mitochondrial encephalomyopathy, and some cancers, making it a focus of metabolic and neurodegenerative disease research.

MT-ND1 antibodies are essential tools for studying mitochondrial function, protein expression, and localization. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess MT-ND1 levels in tissues or cells, particularly in models of mitochondrial dysfunction. Researchers also employ these antibodies to investigate the impact of mtDNA mutations, environmental stressors, or pharmacological interventions on Complex I integrity and energy metabolism.

High-quality MT-ND1 antibodies are validated for specificity using knockout controls or siRNA-based silencing. Commercial antibodies are typically raised in rabbits or mice, with reactivity across species like humans, mice, and rats. Applications span basic research, clinical diagnostics (e.g., identifying mitochondrial defects in biopsies), and drug development targeting ETC disorders. Proper validation ensures reliable detection, as cross-reactivity with other Complex I subunits or degraded proteins can compromise results.